Project profile: Mol Cancer Med
Developing Molecular Medicines for Cancer in the Post - Genome Era
Acronym: Mol Cancer Med
Project Number: LSH-CT-2004-502943
EC Contribution: 4,000.000 Euros
Duration: 48 months
Starting date: 01/10/04
Instrument: Integrated Project
Coordinator: Professor R F Newbold, Institute of Cancer Genetics and Pharmacogenomics, Brunel University, Uxbridge, Middlesex, UB8 3PH, UK
Email: robert.newbold@brunel.ac.uk
Project website: www.brunel.ac.uk/mol-cancer-med
Short summary: The cellular immortality enzyme telomerase (one of the Most promising universal cancer markers) and associated telomere maintenance mechanisms represent novel anti-cancer targets of enormous therapeutic and diagnostic potential. In Mol Cancer Med, a multinational EU translational cancer research consortium has been established, in which expert cancer geneticists and molecular biologists will interact with prominent pharmacologists, clinicians and pathologists to develop, within a 4-year time-frame, these exciting new cellular targets into measurable pre-clinical advances.
